← Back to Search

Color Correcting Lenses

Color Correcting Lenses for Color Blindness

N/A

Waitlist Available

Led By Jeffrey Rabin

Research Sponsored by University of the Incarnate Word

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Hereditary color vision deficient (CVDs) verified by failing scores on the red-green anomaloscope (outside system normal range) and Ishihara testing (3 or more errors on 14 testable plates)

No reported history of eye, systemic or ocular disease

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 weeks

Awards & highlights

Study Summary

This trial shows that color-correcting lenses improve color vision in people with deficiencies.

Who is the study for?

This trial is for individuals with hereditary color vision deficiencies (CVDs) who have normal eye health and a visual acuity of at least 20/30. It's also open to those with normal color vision as controls. People using sleep or wakefulness drugs, or those with eye diseases are excluded.Check my eligibility

What is being tested?

The study tests if wearing color-correcting lenses can improve the color vision in people with CVDs. Participants will be split into groups; some start with placebo lenses then switch to color-correcting ones, while others do the opposite.See study design

What are the potential side effects?

Since this trial involves non-invasive lenses similar to regular contact lenses, side effects may include discomfort while wearing them, potential eye irritation or strain.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a confirmed hereditary color vision deficiency.

Select...

I have no history of eye or systemic diseases.

Select...

My vision is at least 20/30 in both eyes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Color Identification Test

Color Matching

Cone Contrast Naming Test

+3 more

Trial Design

5Treatment groups

Experimental Treatment

Active Control

Placebo Group

Group I: Crossover: Placebo to ExperimentalExperimental Treatment1 Intervention

Placebo Group 1 crosses over to become Experimental Group 2 which includes baseline testing with and without color correcting lenses, followed by 7 days of wear, minimum 3 hours/day, followed by retesting with and without color correcting lenses.

Group II: Color Vision Deficient with Color Correcting LensesExperimental Treatment1 Intervention

10 subjects confirmed to have hereditary color vision deficiency randomly assigned to experimental group 1 which includes baseline testing with and without color correcting lenses, followed by 7 days of wear, minimum 3 hours/day, followed by retesting with and without color correcting lenses.

Group III: Control Group: Subjects with Normal Color VisionActive Control1 Intervention

Fifteen subjects confirmed to have normal color vision will be tested in a single session to determine whether color correcting lenses affect color vision in color vision normal subjects and to provided normative data for several unique measures of color vision performance

Group IV: Crossover: Experimental to PlaceboPlacebo Group1 Intervention

Experimental Group 1 crosses over to become Placebo Group 2 which includes baseline testing with and without placebo lenses, followed by 7 days of wear, minimum 3 hours/day, followed by retesting with and without placebo lenses.

Group V: Color Vision Deficient with Placebo LensesPlacebo Group1 Intervention

10 subjects confirmed to have hereditary color vision deficiency randomly assigned to Placebo Group 1 which includes baseline testing with and without placebo lenses, followed by 7 days of wear, minimum 3 hours/day, followed by retesting with and without placebo lenses.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Placebo Group 1 Crosses over to become Experimental Group 2: Color Correcting Lenses

2022

N/A

~40

Experimental Group 1: Color Correcting Lenses

2022

N/A

~40

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of the Incarnate WordLead Sponsor

17 Previous Clinical Trials

2,474 Total Patients Enrolled

National Eye Institute (NEI)NIH

546 Previous Clinical Trials

1,401,893 Total Patients Enrolled

Jeffrey RabinPrincipal InvestigatorC

Media Library

Color Correcting Lenses (Color Correcting Lenses) Clinical Trial Eligibility Overview. Trial Name: NCT05463016 — N/A

Color Blindness Research Study Groups: Crossover: Experimental to Placebo, Color Vision Deficient with Color Correcting Lenses, Color Vision Deficient with Placebo Lenses, Crossover: Placebo to Experimental, Control Group: Subjects with Normal Color Vision

Color Blindness Clinical Trial 2023: Color Correcting Lenses Highlights & Side Effects. Trial Name: NCT05463016 — N/A

Color Correcting Lenses (Color Correcting Lenses) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05463016 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent is the research team recruiting new participants?

"Affirmative. As documented on clinicaltrials.gov, this medical trial is now calling for enrolment from patients and was first published on July 28th 2022, with the most recent update taking place the same day. 35 individuals are being sought after at a single location."

Answered by AI

Is the enrollment period for this research project currently open?

"Affirmative, the records on clinicaltrials.gov demonstrate that this medical trial is still recruiting participants. The study was unveiled on July 28th 2022 and has most recently been updated in the same month of the same year; thirty-five patients must be recruited from one centre for it to move forward."

Answered by AI